CR10757A - Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro- imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile - Google Patents

Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro- imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile

Info

Publication number
CR10757A
CR10757A CR10757A CR10757A CR10757A CR 10757 A CR10757 A CR 10757A CR 10757 A CR10757 A CR 10757A CR 10757 A CR10757 A CR 10757A CR 10757 A CR10757 A CR 10757A
Authority
CR
Costa Rica
Prior art keywords
quinolin
methyl
crystall
propionitrile
imidazo
Prior art date
Application number
CR10757A
Other languages
English (en)
Inventor
Frank Stowasser
Markus Banziger
Sudhakar Devidasrao Garad
Original Assignee
Ist Ric Biol Molecolare P Angeleti Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39345299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ist Ric Biol Molecolare P Angeleti Spa filed Critical Ist Ric Biol Molecolare P Angeleti Spa
Publication of CR10757A publication Critical patent/CR10757A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR10757A 2006-11-20 2009-04-29 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro- imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile CR10757A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648306P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
CR10757A true CR10757A (es) 2009-06-11

Family

ID=39345299

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10757A CR10757A (es) 2006-11-20 2009-04-29 Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro- imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile

Country Status (35)

Country Link
US (2) US8436177B2 (es)
EP (2) EP2094700B1 (es)
JP (2) JP5562033B2 (es)
KR (3) KR20140091718A (es)
CN (5) CN109970735A (es)
AR (1) AR064256A1 (es)
AU (1) AU2007323820B2 (es)
BR (1) BRPI0719112A2 (es)
CA (1) CA2669199C (es)
CL (1) CL2007003316A1 (es)
CO (1) CO6382134A2 (es)
CR (1) CR10757A (es)
DO (1) DOP2009000116A (es)
EA (1) EA015677B1 (es)
EC (1) ECSP099340A (es)
GE (1) GEP20125436B (es)
GT (1) GT200900133A (es)
HR (1) HRP20140627T1 (es)
IL (2) IL198467A (es)
JO (1) JO2903B1 (es)
MA (1) MA30967B1 (es)
MX (1) MX2009005360A (es)
MY (1) MY150216A (es)
NI (1) NI200900091A (es)
NO (1) NO20092227L (es)
NZ (1) NZ576357A (es)
PE (2) PE20081780A1 (es)
PH (1) PH12013502100A1 (es)
RS (1) RS53335B (es)
SM (1) SMP200900041B (es)
TN (1) TN2009000191A1 (es)
TW (2) TW201402567A (es)
UA (1) UA98473C2 (es)
UY (1) UY30728A1 (es)
WO (1) WO2008064093A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2474323A3 (en) * 2008-03-26 2012-10-10 Novartis AG Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
MA33332B1 (fr) 2009-06-04 2012-06-01 Novartis Ag Dérivés de la 1h-imidazo[4,5-c]quinolinone
BR112012019459A2 (pt) 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
CA2848065A1 (en) * 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Method of treating mucoepidermoid carcinoma
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9913844B2 (en) * 2013-03-21 2018-03-13 Novartis Ag Combination therapy
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106831722B (zh) 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
JP2020500930A (ja) 2016-11-23 2020-01-16 ノバルティス アーゲー エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN111187181B (zh) * 2019-11-22 2023-05-05 吉林大学 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
RU2006121646A (ru) * 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20090080530A (ko) 2009-07-24
JP2010510240A (ja) 2010-04-02
EP2094700B1 (en) 2014-04-02
TN2009000191A1 (en) 2010-10-18
KR20140129396A (ko) 2014-11-06
NI200900091A (es) 2010-02-17
IL198467A0 (en) 2010-02-17
NZ576357A (en) 2011-01-28
CN102993202A (zh) 2013-03-27
KR20140091718A (ko) 2014-07-22
PH12013502100A1 (en) 2015-09-21
NO20092227L (no) 2009-08-17
CO6382134A2 (es) 2012-02-15
AU2007323820A1 (en) 2008-05-29
RS53335B (sr) 2014-10-31
TW200827356A (en) 2008-07-01
IL198467A (en) 2014-11-30
EP2364981A1 (en) 2011-09-14
JP5562033B2 (ja) 2014-07-30
MY150216A (en) 2013-12-13
CN101541793A (zh) 2009-09-23
AR064256A1 (es) 2009-03-25
EA015677B1 (ru) 2011-10-31
JP2013173788A (ja) 2013-09-05
TW201402567A (zh) 2014-01-16
WO2008064093A2 (en) 2008-05-29
UA98473C2 (ru) 2012-05-25
WO2008064093A3 (en) 2008-08-14
US20100168153A1 (en) 2010-07-01
UY30728A1 (es) 2008-07-03
IL219877A0 (en) 2012-06-28
DOP2009000116A (es) 2009-05-31
PE20120083A1 (es) 2012-03-01
SMP200900041B (it) 2009-09-07
CN106045993A (zh) 2016-10-26
HRP20140627T1 (hr) 2014-09-26
TWI417292B (zh) 2013-12-01
MA30967B1 (fr) 2009-12-01
GT200900133A (es) 2010-05-21
CA2669199C (en) 2015-12-29
CN102336752A (zh) 2012-02-01
SMAP200900041A (it) 2009-07-14
PE20081780A1 (es) 2009-01-01
EA200900638A1 (ru) 2009-12-30
US8436177B2 (en) 2013-05-07
JO2903B1 (en) 2015-09-15
CN109970735A (zh) 2019-07-05
AU2007323820B2 (en) 2012-02-23
EP2094700A2 (en) 2009-09-02
CA2669199A1 (en) 2008-05-29
CL2007003316A1 (es) 2008-06-27
GEP20125436B (en) 2012-03-26
ECSP099340A (es) 2009-06-30
HK1132739A1 (en) 2010-03-05
MX2009005360A (es) 2009-06-05
US20130289064A1 (en) 2013-10-31
BRPI0719112A2 (pt) 2013-12-10

Similar Documents

Publication Publication Date Title
IL219877A0 (en) Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
FR18C1049I2 (fr) Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one
SMT201700005B (it) 4-(8-metossi-1-((1-metossipropan-2-il)-2-(tetraidro-2h-piran-4-il)-1h-imidazo[4,5- c]chinolin-7-il)-3,5-dimetilisossazolo e suo uso come inibitore di bromodominio
DK1888578T3 (da) 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolinyl)-phenyl]-propionitril som lipidkinaseinhibitor
WO2009117482A8 (en) Mtor inhibitor salt forms
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
GB2463380B (en) Tubular running tool and methods of use
BRPI0910346A2 (pt) compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso
SMT201600278B (it) Inibitori della benzossazolo chinasi e metodi d'uso
EP1999130A4 (en) Pyridopyrimidine derivatives and their use as PDE4 inhibitors
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0918492A2 (pt) uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
IL208838A0 (en) Purine pi3k inhibitor compounds and methods of use
BRPI0922344A2 (pt) inibidores de tfpi e métodos de uso
DK2545918T3 (da) Pyrazolopyridinderivater som NADPH-oxidaseinhibitorer
BRPI0922090A2 (pt) composição líquida ou líquida-congelada, método para estabilizar uma composição líquida ou líquida-congelada, e, uso de manitol
BRPI0808813A2 (pt) método para a preparação de compostos de borracha, e, uso de compostos
BRPI0913632A2 (pt) derivativos de 6-estradiol substituido e métodos de uso
BRPI0923878A2 (pt) Inibidores de giyt1 bicíclicos 3.1.0 e métodos de produção e uso dos mesmos.
ITMI20052204A1 (it) Uso di colostro per la profilassi delle sindroni influenzali
BRPI0921840A2 (pt) produto compreendendo o composto inibidor de p70 s6 quinase e inibidor de mtor, composto inibidor de p70 s6 quinase e uso do mesmo